Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
microRNA 548l (miR-548l) is a member of the non-coding microRNA family endogenously expressed in humans, encoded by the MIR548L gene. It acts as a regulatory RNA molecule, playing a significant role in cancer biology, especially in non-small cell lung cancer (NSCLC). miR-548l regulates important cellular functions, particularly by targeting the AKT1 gene involved in the PI3K/AKT/mTOR signaling pathway, which affects cancer cell proliferation, migration, invasion, and metastasis. Overexpression of miR-548l suppresses NSCLC cell migration and invasion, while a low level of miR-548l is associated with lymph node metastasis. Its regulatory effects are mediated, in part, by downregulation of AKT1, which leads to decreased mTOR, MMP-2, and MMP-9 expression, all important for cancer aggression and spread. Current data suggests miR-548l is not a druggable therapeutic target itself (e.g., not a receptor, enzyme, transporter), but rather a regulatory RNA with potential as a biomarker or indirect therapeutic node[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on microRNA 548l (miR-548l).